

Eugenii A. Rabiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8910450/publications.pdf>

Version: 2024-02-01

173
papers

12,106
citations

20817

60
h-index

30087

103
g-index

177
all docs

177
docs citations

177
times ranked

11518
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. <i>Psychopharmacology</i> , 2022, 239, 3439-3445. | 3.1 | 8 |
| 2 | Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [¹¹ C]PHNO PET. <i>Neuropsychopharmacology</i> , 2022, 47, 1405-1412. | 5.4 | 9 |
| 3 | Clia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129. | 3.9 | 18 |
| 4 | Relationship between astrocyte reactivity, using novel ¹¹ C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. <i>Molecular Psychiatry</i> , 2022, 27, 2019-2029. | 7.9 | 19 |
| 5 | Test-retest variability and reference region-based quantification of ¹⁸ F-BCPP-EF for imaging mitochondrial complex I in the human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 771-779. | 4.3 | 15 |
| 6 | The Effects of Kisspeptin on Brain Response to Food Images and Psychometric Parameters of Appetite in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1837-1848. | 3.6 | 15 |
| 7 | Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [¹¹ C]-PBR28 blocking study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3530-3539. | 6.4 | 4 |
| 8 | Pharmacokinetics and brain sigma 1 (σ1) receptor occupancy of MR309, a selective σ1 receptor antagonist. <i>British Journal of Clinical Pharmacology</i> , 2021, . . | 2.4 | 0 |
| 9 | The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. <i>Translational Psychiatry</i> , 2021, 11, 393. | 4.8 | 27 |
| 10 | Kisspeptin modulates gamma-aminobutyric acid levels in the human brain. <i>Psychoneuroendocrinology</i> , 2021, 129, 105244. | 2.7 | 11 |
| 11 | Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using ¹¹ C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855. | 7.9 | 43 |
| 12 | Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [¹¹ C]-PHNO PET study. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 52-56. | 2.2 | 4 |
| 13 | Acute acetate administration increases endogenous opioid levels in the human brain: A [¹¹ C]carfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , 2021, 35, 606-610. | 4.0 | 3 |
| 14 | The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169. | 2.2 | 11 |
| 15 | Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2020, 25, 1749-1758. | 7.9 | 23 |
| 16 | Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 451-489. | 6.4 | 86 |
| 17 | Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: ¹⁸ F-BCPP-EF, ¹¹ C-SA-4503, and ¹¹ C-UCB-J. <i>Journal of Nuclear Medicine</i> , 2020, 61, 96-103. | 5.0 | 53 |
| 18 | Serotonin release measured in the human brain: a PET study with [¹¹ C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020, 45, 804-810. | 5.4 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2581. | 4.1 | 20 |
| 20 | Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. <i>Frontiers in Neurology</i> , 2020, 11, 541377. | 2.4 | 9 |
| 21 | Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. <i>Nature Communications</i> , 2020, 11, 246. | 12.8 | 148 |
| 22 | DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. <i>Neurotherapeutics</i> , 2020, 17, 1120-1141. | 4.4 | 18 |
| 23 | Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle α 2A in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427. | 3.9 | 48 |
| 24 | Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men. <i>JCI Insight</i> , 2020, 5, . | 5.0 | 24 |
| 25 | PET Radioligands for imaging of the PDE10A in human: current status. <i>Neuroscience Letters</i> , 2019, 691, 11-17. | 2.1 | 13 |
| 26 | Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ^{11}C -BU99008 PET study. <i>Brain</i> , 2019, 142, 3116-3128. | 7.6 | 73 |
| 27 | Reduced mu opioid receptor availability in schizophrenia revealed with ^{11}C -carfentanil positron emission tomographic Imaging. <i>Nature Communications</i> , 2019, 10, 4493. | 12.8 | 30 |
| 28 | Accuracy and reliability of ^{11}C PBR28 specific binding estimated without the use of a reference region. <i>NeuroImage</i> , 2019, 188, 102-110. | 4.2 | 18 |
| 29 | Serotonergic pathology and disease burden in the premotor and motor phase of A53T α -synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759. | 10.2 | 70 |
| 30 | Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1505-1515. | 3.9 | 15 |
| 31 | The application of positron emission tomography (PET) imaging in CNS drug development. <i>Brain Imaging and Behavior</i> , 2019, 13, 354-365. | 2.1 | 32 |
| 32 | Cerebral serotonin transporter measurements with ^{11}C DASB: A review on acquisition and preprocessing across 21 PET centres. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 210-222. | 4.3 | 25 |
| 33 | Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1125-1132. | 5.0 | 46 |
| 34 | Evaluation of ^{11}C -BU99008, a PET Ligand for the Imidazoline ₂ Binding Site in Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1597-1602. | 5.0 | 61 |
| 35 | ^{11}C -DPA-713 has much greater specific binding to translocator protein 18kDa (TSPO) in human brain than ^{11}C -PK11195. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 393-403. | 4.3 | 51 |
| 36 | Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 516-522. | 5.0 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Imaging Synaptic Density: A Different Look at Neurologic Diseases. <i>Journal of Nuclear Medicine</i> , 2018, 59, 380-381. | 5.0 | 12 |
| 38 | Quantification of human brain PDE4 occupancy by GSK356278: A [¹¹ C](R)-rolipram PET study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2033-2040. | 4.3 | 6 |
| 39 | Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions. <i>JCI Insight</i> , 2018, 3, . | 5.0 | 26 |
| 40 | First evaluation of PET-based human biodistribution and radiation dosimetry of ¹¹ C-BU99008, a tracer for imaging the imidazoline2 binding site. <i>EJNMMI Research</i> , 2018, 8, 71. | 2.5 | 12 |
| 41 | PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018, 33, 1961-1965. | 3.9 | 38 |
| 42 | Disease-related patterns of in vivo pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425. | 6.4 | 26 |
| 43 | Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2017, 81, 941-948. | 1.3 | 32 |
| 44 | Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [¹¹ C]PBR28 PET study. <i>Translational Psychiatry</i> , 2017, 7, e996-e996. | 4.8 | 56 |
| 45 | Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1469-1478. | 3.0 | 23 |
| 46 | Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2679-2690. | 4.3 | 153 |
| 47 | ¹¹ C-PBR28 and ¹⁸ F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1477-1482. | 5.0 | 57 |
| 48 | Evidence for GABA _A receptor dysregulation in gambling disorder: correlation with impulsivity. <i>Addiction Biology</i> , 2017, 22, 1601-1609. | 2.6 | 24 |
| 49 | Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. <i>Brain</i> , 2017, 140, 2927-2938. | 7.6 | 75 |
| 50 | <i>TSPO</i> mutations in rats and a human polymorphism impair the rate of steroid synthesis. <i>Biochemical Journal</i> , 2017, 474, 3985-3999. | 3.7 | 80 |
| 51 | Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593. | 1.1 | 30 |
| 52 | Imaging in Central Nervous System Drug Discovery. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 89-98. | 4.6 | 38 |
| 53 | Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [¹⁸ F]GSK2647544 in Healthy Male Subjects. <i>Molecular Imaging and Biology</i> , 2017, 19, 153-161. | 2.6 | 13 |
| 54 | Comparison of four ¹¹ C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176 based on recent publications that measured specific-to-non-displaceable ratios. <i>EJNMMI Research</i> , 2017, 7, 84. | 2.5 | 80 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Kisspeptin modulates sexual and emotional brain processing in humans. <i>Journal of Clinical Investigation</i> , 2017, 127, 709-719. | 8.2 | 85 |
| 56 | Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248. | 0.6 | 37 |
| 57 | Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 72-81. | 4.4 | 118 |
| 58 | Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1-Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using ¹¹ C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1905-1912. | 5.0 | 18 |
| 59 | Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. <i>Neurology</i> , 2016, 87, 2451-2456. | 1.1 | 32 |
| 60 | Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2619-2629. | 1.9 | 12 |
| 61 | Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. <i>Neuropsychopharmacology</i> , 2016, 41, 1742-1750. | 5.4 | 96 |
| 62 | Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. <i>Biological Psychiatry</i> , 2016, 80, 62-72. | 1.3 | 103 |
| 63 | Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹ C]JMA107. <i>American Journal of Psychiatry</i> , 2016, 173, 714-721. | 7.2 | 33 |
| 64 | Neuroinflammation in treated HIV-positive individuals. <i>Neurology</i> , 2016, 86, 1425-1432. | 1.1 | 136 |
| 65 | Human Kinetic Modeling of the 5HT6 PET Radioligand ¹¹ C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1901-1909. | 5.0 | 24 |
| 66 | The impact of the rs6971 polymorphism in TSPO for quantification and study design. <i>Clinical and Translational Imaging</i> , 2015, 3, 417-422. | 2.1 | 28 |
| 67 | Further evaluation of [¹¹ C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. <i>Synapse</i> , 2015, 69, 86-95. | 1.2 | 18 |
| 68 | Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , 2015, 138, 3016-3029. | 7.6 | 90 |
| 69 | In vivo occupancy of the 5-HT1A receptor by a novel pan 5-HT1(A/B/D) receptor antagonist, GSK588045, using positron emission tomography. <i>Neuropharmacology</i> , 2015, 92, 44-48. | 4.1 | 4 |
| 70 | Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , 2015, 138, 3003-3015. | 7.6 | 100 |
| 71 | Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. <i>European Neuropsychopharmacology</i> , 2015, 25, 1201-1224. | 0.7 | 53 |
| 72 | The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. <i>Journal of Psychopharmacology</i> , 2015, 29, 943-960. | 4.0 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 438-446. | 6.4 | 64 |
| 74 | An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography. <i>EJNMMI Research</i> , 2014, 4, 66. | 2.5 | 23 |
| 75 | Determination of [¹¹ C]PBR28 Binding Potential <i>in vivo</i> : A First Human TSPO Blocking Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 989-994. | 4.3 | 117 |
| 76 | Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [11C]MP-10 PET rodent imaging study with ex vivo confirmation. <i>Translational Psychiatry</i> , 2014, 4, e376-e376. | 4.8 | 16 |
| 77 | In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. <i>Neuropsychopharmacology</i> , 2014, 39, 1703-1712. | 5.4 | 53 |
| 78 | A Graphical Method to Compare the <i>in vivo</i> Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [¹¹ C]PBR28 and [¹⁸ F]PBR111 for TSPO Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1162-1168. | 4.3 | 38 |
| 79 | Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 2069-2074. | 2.1 | 85 |
| 80 | Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. <i>Journal of Psychopharmacology</i> , 2014, 28, 244-253. | 4.0 | 19 |
| 81 | Connectivity-Based Functional Analysis of Dopamine Release in the Striatum Using Diffusion-Weighted MRI and Positron Emission Tomography. <i>Cerebral Cortex</i> , 2014, 24, 1165-1177. | 2.9 | 276 |
| 82 | Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. <i>Molecular Psychiatry</i> , 2014, 19, 427-432. | 7.9 | 80 |
| 83 | Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET. <i>Neuropsychopharmacology</i> , 2014, 39, 866-874. | 5.4 | 43 |
| 84 | Unexpectedly high affinity of a novel histamine H ₃ receptor antagonist, GSK239512, <i>in vivo</i> in human brain, determined using PET. <i>British Journal of Pharmacology</i> , 2014, 171, 1241-1249. | 5.4 | 32 |
| 85 | In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with [¹⁸ F]PBR111 PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1112-1118. | 5.0 | 82 |
| 86 | Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. <i>Journal of Nuclear Medicine</i> , 2014, 55, 595-601. | 5.0 | 50 |
| 87 | Dopamine D3 receptor ligands for drug addiction treatment. <i>Progress in Brain Research</i> , 2014, 211, 255-275. | 1.4 | 47 |
| 88 | Relationship Between Glycine Transporter 1 Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates. <i>Neuropsychopharmacology</i> , 2014, 39, 2742-2749. | 5.4 | 22 |
| 89 | Translational PET imaging research. <i>Neurobiology of Disease</i> , 2014, 61, 32-38. | 4.4 | 51 |
| 90 | PET neuroimaging: The elephant unpacks his trunk. <i>NeuroImage</i> , 2014, 94, 408-410. | 4.2 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Imaging the Dopamine D3 Receptor In Vivo. , 2014, , 265-287. | | 3 |
| 92 | Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. American Journal of Drug and Alcohol Abuse, 2013, 39, 433-440. | 2.1 | 14 |
| 93 | Quantification of the Specific Translocator Protein Signal of ¹⁸ F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. Journal of Nuclear Medicine, 2013, 54, 1915-1923. | 5.0 | 105 |
| 94 | Mathematical modelling of [¹¹ C]-(+)-PHNO human competition studies. NeuroImage, 2013, 68, 119-132. | 4.2 | 33 |
| 95 | Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18kDa Translocator Protein (TSPO). Psychoneuroendocrinology, 2013, 38, 2826-2829. | 2.7 | 47 |
| 96 | Kinetic Analysis of Drug-Target Interactions with PET for Characterization of Pharmacological Hysteresis. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 700-707. | 4.3 | 13 |
| 97 | Occupancy of Brain Dopamine D3 Receptors and Drug Craving: A Translational Approach. Neuropsychopharmacology, 2013, 38, 302-312. | 5.4 | 76 |
| 98 | Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. Journal of Psychopharmacology, 2013, 27, 424-434. | 4.0 | 57 |
| 99 | Awake Nonhuman Primate Brain PET Imaging with Minimal Head Restraint: Evaluation of GABA _A -Benzodiazepine Binding with ¹¹ C-Flumazenil in Awake and Anesthetized Animals. Journal of Nuclear Medicine, 2013, 54, 1962-1968. | 5.0 | 19 |
| 100 | Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?. Synapse, 2013, 67, 909-912. | 1.2 | 21 |
| 101 | Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 311-317. | 2.5 | 16 |
| 102 | Radiosynthesis and Characterization of ¹¹ C-GSK215083 as a PET Radioligand for the 5-HT6 Receptor. Journal of Nuclear Medicine, 2012, 53, 295-303. | 5.0 | 53 |
| 103 | Within-Subject Comparison of [¹¹ C]-(+)-PHNO and [¹¹ C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 127-136. | 4.3 | 150 |
| 104 | An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1-5. | 4.3 | 642 |
| 105 | Dynamic, Adaptive Changes in MAO-A Binding after Alterations in Substrate Availability: An <i>in vivo</i> [¹¹ C]-Harmine Positron Emission Tomography Study. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 443-446. | 4.3 | 27 |
| 106 | Orbitofrontal Connectivity with Resting-State Networks Is Associated with Midbrain Dopamine D3 Receptor Availability. Cerebral Cortex, 2012, 22, 2784-2793. | 2.9 | 62 |
| 107 | Radiation dose estimates for carbon-11-labelled PET tracers. Nuclear Medicine and Biology, 2012, 39, 305-314. | 0.6 | 42 |
| 108 | Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. Biological Psychiatry, 2012, 72, 371-377. | 1.3 | 104 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. <i>NeuroImage</i> , 2012, 60, 902-910. | 4.2 | 73 |
| 110 | Affinity and selectivity of [¹¹ C]-(+)-PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. <i>Synapse</i> , 2012, 66, 489-500. | 1.2 | 74 |
| 111 | The Development, Past Achievements, and Future Directions of Brain PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1426-1454. | 4.3 | 119 |
| 112 | Biodistribution and Radiation Dosimetry of the Serotonin 5-HT ₆ Ligand [¹¹ C]GSK215083 Determined from Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2012, 14, 517-521. | 2.6 | 7 |
| 113 | Positron emission tomography molecular imaging for drug development. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 175-186. | 2.4 | 263 |
| 114 | A pharmacokinetic PET study of NK1 receptor occupancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 226-235. | 6.4 | 28 |
| 115 | Psychiatry "Relevance with Respect to Drug Development, Examples. , 2012, , 535-557. | | 0 |
| 116 | Evaluation of Novel N ¹ -Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 366-373. | 6.4 | 25 |
| 117 | Imaging dopamine receptors in humans with [¹¹ C]-(+)-PHNO: Dissection of D3 signal and anatomy. <i>NeuroImage</i> , 2011, 54, 264-277. | 4.2 | 359 |
| 118 | The Gut Hormones PYY ₃₋₃₆ and GLP-1 ₇₋₃₆ amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans. <i>Cell Metabolism</i> , 2011, 14, 700-706. | 16.2 | 288 |
| 119 | Non-invasive imaging in experimental medicine for drug development. <i>Current Opinion in Pharmacology</i> , 2011, 11, 501-507. | 3.5 | 32 |
| 120 | In vitro assessment of the agonist properties of the novel 5-HT _{1A} receptor ligand, CUMI-101 (MMP), in rat brain tissue. <i>Nuclear Medicine and Biology</i> , 2011, 38, 273-277. | 0.6 | 23 |
| 121 | Radiosynthesis and in vivo evaluation of [¹¹ C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. <i>Nuclear Medicine and Biology</i> , 2011, 38, 875-884. | 0.6 | 42 |
| 122 | A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [¹⁸ F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1241-1256. | 2.6 | 86 |
| 123 | Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 944-952. | 4.3 | 59 |
| 124 | Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. <i>Molecular Psychiatry</i> , 2011, 16, 826-835. | 7.9 | 89 |
| 125 | Positron emission tomography imaging of dopamine D _{2/3} receptors in the human cortex with [¹¹ C]FLB 457: Reproducibility studies. <i>Synapse</i> , 2011, 65, 35-40. | 1.2 | 41 |
| 126 | Evaluation of dopamine D _{2/3} -specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹ C]FLB 457: Implications for measuring cortical dopamine release. <i>Synapse</i> , 2011, 65, 991-997. | 1.2 | 35 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Characterization of in vivo pharmacological properties and sensitivity to endogenous serotonin of [¹¹ C] P943: A positron emission tomography study in <i>Papio anubis</i> . Synapse, 2011, 65, 1119-1127. | 1.2 | 28 |
| 128 | Translational characterization of [¹¹ C]GSK931145, a PET ligand for the glycine transporter type 1. Synapse, 2011, 65, 1319-1332. | 1.2 | 46 |
| 129 | Molecular and functional neuroimaging of human opioid receptor pharmacology. Molecular Psychiatry, 2011, 16, 785-785. | 7.9 | 10 |
| 130 | In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [¹¹ C]-(+)-PHNO. Neuropsychopharmacology, 2011, 36, 887-895. | 5.4 | 41 |
| 131 | Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain. Neuropsychopharmacology, 2011, 36, 2258-2265. | 5.4 | 35 |
| 132 | Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. Journal of Nuclear Medicine, 2011, 52, 24-32. | 5.0 | 330 |
| 133 | Opioids and anxiety. Journal of Psychopharmacology, 2011, 25, 1415-1433. | 4.0 | 85 |
| 134 | 5-HT1A receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl- ¹¹ C]WAY-100635. Journal of Affective Disorders, 2010, 123, 77-80. | 4.1 | 32 |
| 135 | No effect of dopamine depletion on the binding of the high-affinity D2/3 radiotracer [¹¹ C]FLB 457 in the human cortex. Synapse, 2010, 64, 879-885. | 1.2 | 14 |
| 136 | Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 46-50. | 4.3 | 231 |
| 137 | Imaging Cortical Dopamine D1 Receptors Using [¹¹ C]NNC112 and Ketanserin Blockade of the 5-HT2A Receptors. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 985-993. | 4.3 | 27 |
| 138 | Two Binding Sites for [³ H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation. Journal of Cerebral Blood Flow and Metabolism, 2010, 30, 1608-1618. | 4.3 | 187 |
| 139 | State hospitals, academic medicine and the decline of health care in South Africa: A cry of support from those who have left for those who stay.. South African Medical Journal, 2010, 100, 74. | 0.6 | 0 |
| 140 | Evaluation of ¹¹ C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. Journal of Nuclear Medicine, 2010, 51, 1021-1029. | 5.0 | 68 |
| 141 | Imaging the D3 receptor in humans in vivo using [¹¹ C](+)-PHNO positron emission tomography (PET). International Journal of Neuropsychopharmacology, 2010, 13, 289. | 2.1 | 24 |
| 142 | Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [¹¹ C]PHNO, and a Selective D3 Receptor Antagonist. Biological Psychiatry, 2010, 68, 392-399. | 1.3 | 140 |
| 143 | Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [¹¹ C] DASB binding in the living human brain. NeuroImage, 2010, 52, 50-54. | 4.2 | 83 |
| 144 | Kinetic Modeling of ¹¹ C-SB207145 Binding to 5-HT ₄ Receptors in the Human Brain In Vivo. Journal of Nuclear Medicine, 2009, 50, 900-908. | 5.0 | 84 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D _{2/3} radiotracers [¹¹ C]FLB 457 and [¹¹ C]fallypride. <i>Synapse</i> , 2009, 63, 447-461. | 1.2 | 127 |
| 146 | In vivo quantification of regional dopamine D ₃ receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. <i>Synapse</i> , 2009, 63, 782-793. | 1.2 | 127 |
| 147 | Serotonin 5-HT _{1A} receptor binding in people with panic disorder: positron emission tomography study. <i>British Journal of Psychiatry</i> , 2008, 193, 229-234. | 2.8 | 166 |
| 148 | Cortical 5-HT _{1A} receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS. <i>Neurology</i> , 2007, 68, 1233-1235. | 1.1 | 21 |
| 149 | Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?. <i>Journal of Psychopharmacology</i> , 2007, 21, 253-258. | 4.0 | 31 |
| 150 | Fibromyalgia patients show an abnormal dopamine response to pain. <i>European Journal of Neuroscience</i> , 2007, 25, 3576-3582. | 2.6 | 362 |
| 151 | Dopamine (D _{2/3}) receptor agonist positron emission tomography radiotracer [¹¹ C]-(+)-PHNO is a D ₃ receptor preferring agonist in vivo. <i>Synapse</i> , 2006, 60, 485-495. | 1.2 | 159 |
| 152 | Positron Emission Tomography Quantification of [¹¹ C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 330-344. | 4.3 | 100 |
| 153 | A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT _{1A} Receptor Binding in Humans. <i>Journal of Neuroscience</i> , 2005, 25, 2586-2590. | 3.6 | 253 |
| 154 | [¹¹ C]-WAY100635 PET demonstrates marked 5-HT _{1A} receptor changes in sporadic ALS. <i>Brain</i> , 2005, 128, 896-905. | 7.6 | 92 |
| 155 | Brain 5-HT _{1A} receptor binding in chronic fatigue syndrome measured using positron emission tomography and [¹¹ C]WAY-100635. <i>Biological Psychiatry</i> , 2005, 57, 239-246. | 1.3 | 100 |
| 156 | PET studies in drug development: Methodological considerations. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 311-315. | 4.0 | 34 |
| 157 | Imaging technologies in drug development: Anxiety and depression. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 323-327. | 4.0 | 2 |
| 158 | Radiolabelling and in vivo evaluation of [¹¹ C]GSK215083 as potential PET radioligand for the 5-HT ₆ receptor in the porcine brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S598-S598. | 4.3 | 7 |
| 159 | The effect of ionic environments on the affinity of D ₂ -dopamine receptor radioligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S616-S616. | 4.3 | 0 |
| 160 | 5-HT _{1A} receptor density and defensive personality - interaction of neurochemistry, personality and depression explored with [¹¹ C]WAY 100635 PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S376-S376. | 4.3 | 0 |
| 161 | Preferential 5-HT _{1A} Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?. <i>Neuropsychopharmacology</i> , 2004, 29, 1688-1698. | 5.4 | 33 |
| 162 | Occupancy of Agonist Drugs at the 5-HT _{1A} Receptor. <i>Neuropsychopharmacology</i> , 2004, 29, 847-859. | 5.4 | 46 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. <i>Molecular Psychiatry</i> , 2004, 9, 386-392. | 7.9 | 231 |
| 164 | Kinetic analysis of neuroreceptor binding using PET. <i>International Congress Series</i> , 2004, 1265, 12-24. | 0.2 | 7 |
| 165 | Tremor in Parkinsonâ€™s disease and serotonergic dysfunction. <i>Neurology</i> , 2003, 60, 601-605. | 1.1 | 277 |
| 166 | Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11]WAY-100635 and [11C]raclopride. <i>Journal of Psychopharmacology</i> , 2002, 16, 195-199. | 4.0 | 40 |
| 167 | 5-Hydroxytryptamine 1A Receptor Occupancy by Novel Full Antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzodioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A [11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide Trihydrochloride (WAY-100635) Positron Emission Tomography Study in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 301, 1144-1150. | 2.5 | 44 |
| 168 | A Database of [11C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables. <i>NeuroImage</i> , 2002, 15, 620-632. | 4.2 | 133 |
| 169 | Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. <i>American Journal of Psychiatry</i> , 2001, 158, 2080-2082. | 7.2 | 80 |
| 170 | Î²-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro Implications for Antidepressant Therapy. <i>Neuropsychopharmacology</i> , 2000, 23, 285-293. | 5.4 | 70 |
| 171 | Brain Serotonin1A Receptor Binding Measured by Positron Emission Tomography With [11C]WAY-100635. <i>Archives of General Psychiatry</i> , 2000, 57, 174. | 12.3 | 597 |
| 172 | Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-11C]WAY-100635. <i>Nuclear Medicine and Biology</i> , 2000, 27, 509-513. | 0.6 | 63 |
| 173 | Tracer Kinetic Modeling of the 5-HT1A Receptor Ligand [carbonyl-11C]WAY-100635 for PET. <i>NeuroImage</i> , 1998, 8, 426-440. | 4.2 | 267 |